文献速递临床微生物分子诊断临床免疫

观点交锋:MRSA鼻拭子检测能否用于非肺炎场景的万古霉素降阶梯?

Point-Counterpoint: Should MRSA nares testing be used as a tool for vancomycin de-escalation outside of pneumonia?
PubMed 文献 · J Clin Microbiol · 2026-04-21

万古霉素广泛用于治疗革兰阳性菌感染,但急性肾损伤发生率可达20%。MRSA定植与感染强相关,鼻拭子筛查对MRSA肺炎有良好阴性预测值,但对其他感染关联证据较弱。本文由临床药学团队与检验科就MRSA鼻拭子核酸检测或培养能否指导非肺炎场景万古霉素降阶梯展开辩论,并回顾临床证据与监管背景。

要点

  • MRSA鼻拭子阴性对MRSA肺炎有良好阴性预测值,但其他感染类型证据较弱。
  • MRSA鼻拭子检测获FDA批准用于定植筛查,非治疗决策用途。
  • 万古霉素相关急性肾损伤可达20%,药代动力学给药方案可降低风险。

核心结论

  • MRSA鼻拭子检测用于非肺炎场景万古霉素降阶梯的合理性存在争议,需权衡临床证据与监管适用范围。

研究设计与样本

  • 本文为观点交锋类文章,由临床药学团队与检验科分别就MRSA鼻拭子检测用于万古霉素降阶梯进行辩论,并回顾相关临床证据与监管背景。

主要发现

  • 万古霉素使用与急性肾损伤相关,发生率可达20%,药代动力学给药方案可降低该风险。
  • MRSA定植与感染强相关,鼻拭子筛查阴性对MRSA肺炎有良好阴性预测值,但对其他感染关联证据较弱。
  • MRSA鼻拭子检测经FDA批准用于MRSA定植检测,而非治疗决策。

关键数值与推荐

  • MRSA鼻拭子阴性对MRSA肺炎有良好阴性预测值,但对其他感染关联证据较弱。
  • 万古霉素相关急性肾损伤发生率可达20%。

临床怎么用

  • 临床可参考MRSA鼻拭子阴性结果辅助MRSA肺炎的万古霉素降阶梯决策。
  • 非肺炎场景使用MRSA鼻拭子指导降阶梯需谨慎,应结合临床证据与监管背景综合判断。

局限性

  • MRSA定植与感染的关联在其他感染类型中证据较弱。
  • MRSA鼻拭子检测未获FDA批准用于治疗决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Vancomycin is broadly used to treat gram-positive infections in both inpatient and outpatient settings. Its use is primarily for the treatment of methicillin-resistant Staphylococcus aureus (MRSA), which is a common cause of pneumonia, skin and soft tissue infections, and bloodstream infections. Vancomycin therapy requires close clinical monitoring to maintain therapeutic efficacy and, importantly, patient safety. Vancomycin use is associated with acute kidney injury in up to 20% of cases, a number that can be driven down by pharmacokinetic dosing protocols. However, the best mitigation against adverse outcomes associated with vancomycin is to ensure it is only used when needed and rapidly de-escalated when not. As such, many stewardship programs, who are tasked with the safe and effective use of antimicrobial agents, have focused on optimizing vancomycin use. There is a strong correlation with MRSA colonization and infection, and a negative MRSA nares screen has a good negative predictive value for MRSA pneumonia (although this association is less well documented for other infections). As such, detection of MRSA in nares swabs, by nucleic acid amplification tests (NAATs) or culture, is a logical tool for stewarding vancomycin. However, the application of MRSA screening tests as MRSA diagnostics is complex, as these tests are cleared by the U.S. Food and Drug Administration for the detection of MRSA colonization, and not for therapeutic decision making. In this issue of the Journal of Clinical Microbiology, the issue of MRSA nares tests is debated by a clinical pharmacy team and the laboratory. The authors review the clinical evidence and regulatory background in which an MRSA nares NAAT may be used to inform treatment decisions.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Ilges D, Dickinson DT, Bosquez JM, et al. Point-Counterpoint: Should MRSA nares testing be used as a tool for vancomycin de-escalation outside of pneumonia? J Clin Microbiol. 2026. PMID: 42012220. doi:10.1128/jcm.01309-25

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。